# US 2015/0147298 A1 · Sleep enhancement with cortisol reduction medical food

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147298 A1
- Document ID: US20150147298A1
- Status: Published application
- Kind: A1
- Application number: 14/544,274
- Filed: 2014-12-17
- Published: 2015-05-28
- Earliest claimed: 2006-07-24
- Assignees: CortControl, Inc.
- Inventors: John Edgar Menear; Joseph Ramaekers
- Web page: https://patentgrep.com/patent/US20150147298A1

## CPC

- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A23K 10/16: Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions (A23K10/12 takes precedence)
- A23K 20/158: Fatty acids; Fats; Products containing oils or fats
- A23K 20/163: Sugars; Polysaccharides
- A23K 20/168: Steroids
- A23K 40/30: by encapsulating; by coating
- A23K 40/35: Making capsules specially adapted for ruminants
- A23K 50/10: for ruminants
- A23K 50/60: for weanlings
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A23L 33/30: {Dietetic or nutritional methods, e.g. for losing weight (A23L33/10 takes precedence)}
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61K 9/145: {with organic compounds}
- A61K 31/7008: Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A61K 31/716: Glucans
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 36/068: Cordyceps
- A61K 36/07: Basidiomycota, e.g. Cryptococcus
- A61K 36/074: Ganoderma
- A61K 36/076: Poria
- A61K 36/48: Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K 38/02: Peptides of undefined number of amino acids; Derivatives thereof
- A61K 38/1703: {from vertebrates}
- A61K 41/0004: {Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K 2035/11: {Medicinal preparations comprising living procariotic cells}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23K: FODDER
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

A method of using a sleep enhancement medical food to improve human sleep quality. This sleep enhancement medical food consists of transfer factor, lactic acid generating bacteria, and/or glucans in appropriate combinations. The sleep enhancement medical food, administered correctly, reduces cortisol levels. High cortisol causes insomnia. Dosage amounts are adjusted for client weight. Consumption frequency and dosage may be adjusted in response to cortisol measurements. Typically, consumption of the sleep enhancement medical food is done under professional supervision, and may be combined with other treatment strategies.

## Claims

### Claim 1

A food-based method for improving a sleep disorder for a human with high cortisol comprising:
combining transfer factor and lactic acid generating bacteria to create a medical food, where
said transfer factor includes polypeptides with a molecular weight below 10,000 Daltons;
feeding said medical food to said human, where
a dosage level is chosen based on said human's weight, and
the frequency of said feeding is between five times per day and once per week; and
continuing said feeding until restful sleep is achieved.

### Claim 2 (depends on 1)

The food-based method of claim 1 wherein said high cortisol is defined as a cortisol level that exceeds the United States population average.

### Claim 3 (depends on 1)

The food-based method of claim 1 wherein glucans are added to said medical food.

### Claim 4 (depends on 3)

The food-based method of claim 3 wherein said glucans are derived from natural or hybrid mushrooms.

### Claim 5 (depends on 1)

The food-based method of claim 1 further comprising:
measuring night time cortisol levels.

### Claim 6 (depends on 5)

The food-based method of claim 5 further comprising:
adjusting said dosage levels based on said measuring.

### Claim 7 (depends on 3)

The food-based method of claim 3 further comprising:
changing the relative proportions of transfer factor, lactic acid generating bacteria, and
glucans included within each said food dosage.

### Claim 8 (depends on 1)

The food-based method of claim 1 wherein said transfer factor in each said dosage is present at 0.05 to 50 mg per pound of human body weight.

### Claim 9 (depends on 1)

The food-based method of claim 1 wherein said lactic acid generating bacteria in each said dosage is present at 0.47 to 10 mg per pound of human body weight.

### Claim 10 (depends on 9)

The food-based method of claim 9 wherein said lactic acid generating bacteria has a live count of 2.5 million colony forming units per ounce.

### Claim 11 (depends on 3)

The food-based method of claim 3 wherein said glucans in each said dosage is present at 0.1 to 10 mg per pound of human body weight.

### Claim 12 (depends on 3)

The food-based method of claim 3 wherein transfer factor transfer, lactic acid generating bacteria, and glucans are consumed at different times within a one week period.

### Claim 13 (depends on 6)

An improvement upon U.S. Pat. No. 6,962,718, claim 6 (issued Nov. 8, 2005 to Joseph Ramaekers, a current inventor) which recites—
A formulation comprising pharmaceutically acceptable transfer factor and a pharmaceutically acceptable lactic acid generating bacteria wherein the amount of said transfer factor is from 10 mg to 10,000 mg per ounce of formulation;
wherein the improvement comprises the following method-of-use limitation,
feeding said formulation to sleep disorder patients to enhance restful sleep wherein said patients exhibit high cortisol levels.

### Claim 14 (depends on 13)

The improvement claim in claim 13, wherein said feeding includes at least one step selected from a group including:
(a) optimizing proportions of transfer factor transfer and said lactic acid generating bacteria within said formulation to create a sleep improvement medical food, (b) choosing a dosage level of said formulation based on said patient's weight, (c) feeding said patient a dosage between five times per day and one time per week, (d) measuring said patient's cortisol levels periodically, (e) adjusting dosage levels based on periodic cortisol measurements, and (f) monitoring multiple stress hormones.

### Claim 15 (depends on 13)

The improvement claim in claim 13, wherein glucans are added to said formulation.

### Claim 16 (depends on 15)

The improvement claim in claim 15, wherein said glucans are present between at 0.1 to 10 mg per pound of patient's body weight.

### Claim 17

A food-based method for improving sleep quality for a human when high cortisol levels are contributing to sleeplessness comprising:
combining transfer factor transfer and lactic acid generating bacteria to create a medical food, wherein
said transfer factor includes polypeptides with a molecular weight below 10,000 Daltons;
feeding said medical food to said human, wherein
a dosage level is chosen based on said human's weight, and
the frequency of said feeding is between five times per day and once per week; and
utilizing a health care professional or doctor to supervise said improving sleep quality.

### Claim 18

A food-based method for improving depression for a human when high cortisol levels are present comprising:
combining transfer factor and lactic acid generating bacteria to create a medical food, wherein
said transfer factor includes polypeptides with a molecular weight below 10,000 Daltons;
feeding said medical food to said human, wherein
a dosage level is chosen based on said human's weight, and
the frequency of said feeding is between five times per day and once per week; and
continuing said feeding until symptoms of depression are reduced.

### Claim 19

A food-based method for improving diabetes or high blood sugar for a human when high cortisol levels are present comprising:
combining transfer factor and lactic acid generating bacteria to create a medical food, wherein
said transfer factor includes polypeptides with a molecular weight below 10,000 Daltons;
feeding said medical food to said human, wherein
a dosage level is chosen based on said human's weight, and
the frequency of said feeding is between five times per day and once per week; and
continuing said feeding until blood sugar is reduced.

### Claim 20

A food-based method for improving cardiovascular disease for a human when high cortisol levels are present comprising:
combining transfer factor and lactic acid generating bacteria to create a medical food, wherein
said transfer factor includes polypeptides with a molecular weight below 10,000 Daltons;
feeding said medical food to said human, wherein
a dosage level is chosen based on said human's weight, and
the frequency of said feeding is between five times per day and once per week; and
continuing said feeding until cortisol levels are reduced or until said cardiovascular disease improves.

### Claim 21

A food-based method for slowing Alzheimer's progression for a human when high cortisol levels are present comprising:
combining transfer factor and lactic acid generating bacteria to create a medical food, wherein
said transfer factor includes polypeptides with a molecular weight below 10,000 Daltons;
feeding said medical food to said human, wherein
a dosage level is chosen based on said human's weight, and
the frequency of said feeding is between five times per day and once per week; and
continuing said feeding until reduced cortisol levels are achieved or said progression is slowed.

### Claim 22

A food-based method for improving breast cancer treatment for a human when high cortisol levels are present comprising:
combining transfer factor and lactic acid generating bacteria to create a medical food, wherein
said transfer factor includes polypeptides with a molecular weight below 10,000 Daltons;
feeding said medical food to said human, where
a dosage level is chosen based on said human's weight, and
the frequency of said feeding is between five times per day and once per week; and
continuing said feeding during or after said breast cancer treatment.
